Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT06507878
- Status
- Recruiting
Conditions
- Thyroid Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The goal of this clinical research study is to learn about the barriers in the real world to accessing treatments for ATC. And to learn about how patients with ATC tolerate and respond to the commercially available medications for treatment of this disease, outside of a clinical study.
Key Dates
- First listed
- Jul 18, 2024
- Start date
- Dec 5, 2024
- Status verified
- Sep 2026
- Primary completion
- Jul 1, 2032
- Completion
- Jul 1, 2034
Study Design
- Enrollment
- 459 participants (estimated)
Primary Outcome Measure
Overall Survival [ Time Frame: Through study completion; an average of 1 year. ]
Central Contacts
- Priyanka C Iyer, MBBS(832) 291-6069
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| MD Anderson Cancer Center | Houston | Texas | 77030 |
Find similar trials in Houston, TX
By research site
Related Studies
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseRecruiting · Adela, Inc · Duarte, California
- Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TCPHASE2 · Recruiting · Massachusetts General Hospital · Washington D.C., District of Columbia
- Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesPHASE1/PHASE2 · Recruiting · Institut de Recherches Internationales Servier · Gilbert, Arizona
- Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · ModeX Therapeutics, An OPKO Health Company · Denver, Colorado